Work

Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?

Year: 2026

Type: article

Abstract: Bjorn K I Meijers, Thomas Mavrakanas; Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?, Clinical Kidney Journal

Source: Clinical Kidney Journal

DOI: 10.1093/ckj/sfag220

Authors: Bjorn K I Meijers, Thomas A Mavrakanas

Institutions: Universitair Ziekenhuis Leuven, KU Leuven, McGill University Health Centre, Research Institute of the McGill University Health Centre, McGill University

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,335

Funders: Pfizer, AstraZeneca, Nipro, Fonds Wetenschappelijk Onderzoek, KU Leuven, Novo Nordisk

Awards: G3048064032, The intestinal barrier in patients with chronic kidney disease, G4692305740, G564316952, G8551990159, G8775406254

OpenAlex ID: W7166344999

FWCI:

Cites: 10

Cited by:

Related to: